Philip Morris International (PMI) is selling inhaled drug specialist Vectura to Molex Asia Holdings for a fraction of the £1.1 billion ($1.45 billion) it paid for the business three years ago.

Colorado-based Sasaki has been tapped to lead Plan Baton Rouge III, the latest initiative aimed at advancing downtown Baton ...

Vectura's efforts to develop its own therapies met with mixed results, and the company was hit particularly hard in 2018 when it abandoned phase 3 drug candidate VR475 for severe uncontrolled asthma.

Philip Morris International Inc.’s PM shares rallied 9.4% in the pre-market session today after reporting robust fourth-quarter 2024 results. Both top and bottom lines increased year over year and ...

A good illustration of the contradictions that sometimes arise in this complex trading landscape is Philip Morris International's (US:PM) recent sale of its asthma inhaler manufacturer, Vectura, which ...

"The last quarter of the year saw greater movement in the market, with increased demand and willingness to invest. We received more inquiries late in 2024 and look forward to a market on the rise." Mi ...

Greetings and welcome to the Aurora Cannabis Inc. Third Quarter 2025 Results Conference Call. All participants will be in a listen-only mode and a question-and-answer session will follow the formal ...